Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Insufficiency, Chronic: full-pipeline trial registry
3 of 15 indexed Renal Insufficiency, Chronic trials are currently recruiting.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 3 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Renal Insufficiency, Chronic: 15 US clinical trials tracked, 3 recruiting.
Renal Insufficiency, Chronic is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 3 of these trials.
Enrollment posture brief
Registry condition renal-insufficiency-chronic
OPEN 3 | RECR 20% | LATE 5 | EARLY 4 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Renal Insufficiency, Chronic lists 3 open slots (20% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Insufficiency, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Insufficiency, Chronic is recruiting below its size-band peers.
3 of 15 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Renal Insufficiency, Chronic research.
University of Pennsylvania accounts for 3 of 15 trials (20%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Insufficiency, Chronic enrolment sits around 88 participants.
Median target enrolment is 88 among the 15 trials that report a genuine target (sentinel values excluded). 8 of those (53.3%) plan for fewer than 100 participants.
-
Renal Insufficiency, Chronic splits between interventional and observational designs.
10 interventional and 5 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Transformative Research in Diabetic Nephropathy 2.0
University of Pennsylvania
NCT07444203
Neurovascular Transduction During Exercise in Chronic Kidney Disease
Emory University
NCT02947750
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT07426380
SDCC - Prospective Cohort Study of Chronic Renal Insufficiency
University of Pennsylvania
NCT00304148
Penn Produce Prescription and Chronic Kidney Disease Study
University of Pennsylvania
NCT06561412
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
University of Texas Southwestern Medical Center
NCT02791880
Sensitivity and Specificity of NGAL in an Emergency Room Population
Columbia University
NCT00786708
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
USRC Kidney Research
NCT05085275
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
USRC Kidney Research
NCT05951192
Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
Bayer
NCT02064426
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
Abbott
NCT00048516
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
Abbott
NCT00048438
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
Hoffmann-La Roche
NCT03552393
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
FAST BioMedical
NCT03095391
Iron Dosing Pilot Study Using Model Predictive Control
University of Louisville
NCT03633656
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Insufficiency, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Insufficiency, Chronic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Insufficiency, Chronic page
15 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Renal Insufficiency, Chronic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Pennsylvania sponsors the most Renal Insufficiency, Chronic trials on record, review their full trial history before evaluating a specific study. See University of Pennsylvania's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Insufficiency, Chronic condition card totals 15 registered trials; most-linked intervention Ferric Citrate 1 GM Oral Tablet [AURYXIA]; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.